New combo treatment hope for advanced liver cancer patients

NCT ID NCT07157969

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing whether adding interventional procedures (like TACE or HAIC) to a combination of immune checkpoint inhibitors and anti-VEGF drugs works better than the drugs alone for advanced hepatocellular carcinoma. About 300 participants with BCLC stage B or C liver cancer will be enrolled. Researchers will measure how well the tumors shrink and how long patients live without the cancer progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lenvatinib, Pembrolizumab, Atezolizumab, Bevacizumab, Camrelizumab, Apatinib (drugs); TACE, HAIC (procedures)
What this could lead to: If successful, this could point toward a more effective combination treatment for advanced liver cancer, potentially improving tumor shrinkage and survival.
What could go wrong: This is a Phase 2 trial, so results are still early and may not confirm benefit. Combining multiple therapies also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.